|
|
Prepublished online as a Blood First Edition Paper on May 1, 2003; DOI 10.1182/blood-2003-02-0439.

Submitted February 10, 2003
Accepted April 23, 2003
Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and three new ferroportin (slc11A3) mutations
Gilles Hetet, Isabelle Devaux, Nadem Soufir, Bernard Grandchamp, and Carole Beaumont*
INSERM, Unite 409, Faculte Xavier Bichat, Paris, France
Association Claude Bernard, Paris, France
Laboratoire de Biochimie Hormonale et Genetique, Hopital Xavier Bichat, Paris, France
* Corresponding author; email: beaumont{at}bichat.inserm.fr.
Unexplained hyperferritinemia is a common clinical finding, even in asymptomatic persons. When early onset bilateral cataract is also present, the hereditary hyperferritinemia-cataract syndrome (HHCS), due to heterozygous point mutation in the L ferritin IRE sequence, can be suspected. We sequenced the L ferritin exon 1 in 52 DNA samples from patients referred to us for molecular diagnosis of HHCS. We identified 24 samples with a point mutation/deletion in the IRE. For the 28 samples in which no IRE mutation was present, we also genotyped HFE mutations and sequenced both H ferritin and ferroportin genes. We found an increased frequency of H63D heterozygotes (12 out of 28), but no H ferritin mutations. We identified three new ferroportin mutations, producing, respectively, D157G, Q182H and G323V amino acid replacements, suggesting that these patients have dominant type 4 hemochromatosis. This study demonstrates that both L ferritin IRE and ferroportin mutations can account for isolated hyperferritinemia. The presence of cataract does not permit the unambiguous identification of patients with HHCS, although the existence of a family history of cataract was only encountered in these patients. This raises the intriguing possibility that lens ferritin accumulation might be a factor contributing to age-related cataract in the general population. Additional causes of isolated hyperferritinemia remain to be identified.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Camaschella and E. Poggiali
Towards explaining "unexplained hyperferritinemia"
Haematologica,
March 1, 2009;
94(3):
307 - 309.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kannengiesser, A.-M. Jouanolle, G. Hetet, A. Mosser, F. Muzeau, D. Henry, E. Bardou-Jacquet, M. Mornet, P. Brissot, Y. Deugnier, et al.
A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload
Haematologica,
March 1, 2009;
94(3):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Swinkels, M. C.H. Janssen, J. Bergmans, and J. J.M. Marx
Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches
Clin. Chem.,
June 1, 2006;
52(6):
950 - 968.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chlosta, D. S. Fishman, L. Harrington, E. E. Johnson, M. D. Knutson, M. Wessling-Resnick, and B. J. Cherayil
The Iron Efflux Protein Ferroportin Regulates the Intracellular Growth of Salmonella enterica.
Infect. Immun.,
May 1, 2006;
74(5):
3065 - 3067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Schmitt, L. Gouya, E. Malonova, J. Lamoril, J.-M. Camadro, M. Flamme, C. Rose, S. Lyoumi, V. Da Silva, C. Boileau, et al.
Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria
Hum. Mol. Genet.,
October 15, 2005;
14(20):
3089 - 3098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Goralska, S. Nagar, L. N. Fleisher, and M. C. McGahan
Differential Degradation of Ferritin H- and L-Chains: Accumulation of L-Chain-Rich Ferritin in Lens Epithelial Cells
Invest. Ophthalmol. Vis. Sci.,
October 1, 2005;
46(10):
3521 - 3529.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. De Domenico, D. M. Ward, E. Nemeth, M. B. Vaughn, G. Musci, T. Ganz, and J. Kaplan
The molecular basis of ferroportin-linked hemochromatosis
PNAS,
June 21, 2005;
102(25):
8955 - 8960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Schimanski, H. Drakesmith, A. T. Merryweather-Clarke, V. Viprakasit, J. P. Edwards, E. Sweetland, J. M. Bastin, D. Cowley, Y. Chinthammitr, K. J. H. Robson, et al.
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Blood,
May 15, 2005;
105(10):
4096 - 4102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K J H Robson, A T Merryweather-Clarke, E Cadet, V Viprakasit, M G Zaahl, J J Pointon, D J Weatherall, and J Rochette
Recent advances in understanding haemochromatosis: a transition state
J. Med. Genet.,
October 1, 2004;
41(10):
721 - 730.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Biasiotto, S. Belloli, G. Ruggeri, I. Zanella, G. Gerardi, M. Corrado, E. Gobbi, A. Albertini, and P. Arosio
Identification of New Mutations of the HFE, Hepcidin, and Transferrin Receptor 2 Genes by Denaturing HPLC Analysis of Individuals with Biochemical Indications of Iron Overload
Clin. Chem.,
December 1, 2003;
49(12):
1981 - 1988.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|